重组人血管内皮抑制素联合化疗治疗晚期肺腺癌患者的疗效及安全性探析  

Efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with advanced lung adenocarcinoma

作　　者：姜晓红 JIANG Xiao-hong(Department of Radiotherapy,Dandong First Hospital,Dandong 118000,China)

机构地区：[1]丹东市第一医院放疗科,118000

出　　处：《中国实用医药》2023年第10期111-114,共4页China Practical Medicine

摘　　要：目的 分析重组人血管内皮抑制素联合化疗治疗晚期肺腺癌患者的疗效及安全性。方法 80例晚期肺腺癌患者,以随机数字表法分为观察组与对照组,每组40例,对照组给予化疗治疗,观察组在对照组基础上增加重组人血管内皮抑制素治疗。比较两组治疗前后的肿瘤标志物[糖类抗原724(CA724)、癌胚抗原(CEA)]、体液免疫功能指标[免疫球蛋白(Ig)G、IgA]、NK细胞活性、疗效、副反应。结果 治疗后,观察组IgG(9.92±2.71)g/L、IgA(1.96±0.51)g/L、NK细胞活性(51.08±5.14)%高于对照组的(5.41±1.29)g/L、(1.23±0.12)g/L、(38.72±1.13)%,CA724(25.25±5.05)U/ml、CEA(18.01±2.12)μg/ml低于对照组的(38.56±5.45)U/ml、(76.57±12.67)μg/ml,差异有统计学意义(P<0.05)。观察组治疗总有效率75.00%(30/40)高于对照组的52.50%(21/40),差异有统计学意义(P<0.05)。观察组副反应发生率25.00%(10/40)低于对照组的50.00%(20/40),差异有统计学意义(P<0.05)。结论 重组人血管内皮抑制素联合化疗治疗晚期肺腺癌的效果确切,可改善患者的免疫功能和预后,减少毒副反应的发生,具有较高的安全性,值得推广和应用。Objective To analyze the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with advanced lung adenocarcinoma.Methods A total of 80 patients with advanced lung adenocarcinoma were randomly divided into observation group and control group,with 40 cases in each group.The control group was treated with chemotherapy,and the observation group was additionally treated with recombinant human endostatin.Both groups were compared in terms of tumor markers[carbohydrate antigen 724(CA724),carcinoembryonic antigen(CEA)],humoral immune function indicators[immunoglobulin(Ig)G,IgA]and NK cell activity before and after treatment,efficacy,and side effects.Results After treatment,the observation group had IgG of(9.92±2.71)g/L,IgA of(1.96±0.51)g/L and NK cell activity of(51.08±5.14)%,which were higher than those of(5.41±1.29)g/L,(1.23±0.12)g/L and(38.72±1.13)%in the control group;CA724 of(25.25±5.05)U/ml and CEA of(18.01±2.12)μg/ml in the observation group were lower than those of(38.56±5.45)U/ml and(76.57±12.67)μg/ml in the control group;the differences were statistically significant(P<0.05).The total effective rate of 75.00%(30/40)in the observation group was higher than that of 52.50%(21/40)in the control group,and the difference was statistically significant(P<0.05).The incidence of side effects of 25.00%(10/40)in the observation group was lower than that of 50.00%(20/40)in the control group,and the difference was statistically significant(P<0.05).Conclusion Recombinant human endostatin combined with chemotherapy is effective in the treatment of advanced lung adenocarcinoma.It can improve the immune function and prognosis of patients and reduce the occurrence of toxic and side effects.It has high safety and is worthy of popularization and application.

关 键 词：重组人血管内皮抑制素 化疗 晚期肺腺癌 疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]